摘要肿瘤的耐药又分为原发耐药（primary drug resistance,PDR）和多药耐药（mutidrug resistance,MDR），PDR只对诱导药物产生耐药性，MDR则是指肿瘤细胞对一种抗肿瘤药产生耐药性后，对结构与作用机制不同的抗肿瘤药也产生交叉耐药性。肿瘤MDR是导致肿瘤化疗失败的最主要原因。本文就其耐药机制作一综述。
2Sauna ZE, Ambudkar SV. Evidence for a requirement for ATP hydrolysis at two distinct steps during a single turnover of the catalytic of human P glycoprotein. Proc Natl Acad Sci USA,2000,97 (6) : 2515-2520.
3Stein WD, Bates SB, Fojo T. Intractable cancer: the many faces of. multidlug lesistance and the many talgets it plesents fol thelapeutic attack. Curt DlugTalgets,2004,5 (4) : 333 -346.
4Hunault M,Zhou D,Dlemel A,et al. Multidlug lesistance gene explession in acute myeloid leukemia:majol plognosis significance for invivo drag resistance to induction treatment. Ann Hematol, 1997 ,74 (2) :65-71.
5Grant CE,Valdimarsson G,Gerlach JH,et al.Overexpression of multidrug resistance associated protein (MRP) increase resistance to namralproduct drugs.Cancer Res,1994,54 (2) :367-361.
6P e rez Tom 6 s R, Multidrug resistance : retrospect and prospects in anti cancer drug treatment, Curr Med Chem, 2006,13 (16) :1859- 1876.
7Kolberg A, Rosa TG, Puhl MT, et al. Low expression of MRPI / CS X pump ATPase in lymphocytes of Walker 256 tonlour bearing rats is associated with eyelopen tenone prostaglandin aeeunmlation and cancer imnmnodefieieney. Cell Bioehem Fune, 2006,24 ( 1 ) : 23- 39.
8Nooter K,Westerman AM,Flens MJ.Expression of the muhidrug resistance associated protein (MRP) gene in hmnan eaneers.Clin Cancer Res,1995,1 (11) :1301- 1310.
9Ozben T.Meehanisms and strategies to overcome multiple drug resistance in eaneer.FEBS Lett, 2006, 580 (12) : 2903- 2909.
4FRESNO VARA JF,CASADO E ,DE CASTRO J,et al. PI3K/Akt signaling pathway and cancer [ J ]. Cancer Treat Rev, 2004,30 (2) : 193-204.
5OSAKI M,OSHIMURA M,ITO H. PI3K-Akt pathway :its functions and alterations in human cancer [J]. Apoptosis,2004,9 (6):667- 676.
6SUN M ,WANG G ,PACIGA JE ,et al. AKT1/PKB alpha kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells [J]. Am J Pathol,2001,159(2) :431-437.
7MALIK SN , BRATTAIN M , GHOSH PM , et al. Immunohistochemi- cal demonstration of phosphor-akt in high gleason grade prostate cancer[J]. Clin Cancer Res,2002,8(4): 1168-1171.
8HU L , HOFMANN J , LU Y, et al. Inhibition of phosphatidylinositol 3'-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models[J]. Cancer Res,2002,62(4): 1087-1092.
9YUAN ZQ,SUN M ,FELDMAN RI ,et al. Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3- OH kinase/Akt pathway in human ovarian cancer[J].Oncogene , 2000,19(19) :2324-2330.
10TAYLOR CG ,SARGENT JM ,Elgie AW ,et al. The clinical relevance of chemosensitivity testing in ovarian cancer [J].Cancer Detection and Prevention, 1998,22 (4) : 305-312.
4Irene Colavita,Nicola Esposito,Concetta Quintarelli,Ersilia Nigro,Fabrizio Pane,Margherita Ruoppolo,Francesco Salvatore.Identification of Annexin A1 interacting proteins in chronic myeloid leukemia KCL22 cells[J].Proteomics.2013(16)
5Dan Stark,Matthew Nankivell,Eric Pujade-Lauraine,Gunnar Kristensen,Lorraine Elit,Martin Stockler,Felix Hilpert,Andrés Cervantes,Julia Brown,Anne Lanceley,Galina Velikova,Eduardo Sabate,Jacobus Pfisterer,Mark S Carey,Philip Beale,Wendi Qian,Ann Marie Swart,Amit Oza,Tim Perren.Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial[J].Lancet Oncology.2013
6Luca Parente,Egle Solito.Annexin 1: more than an anti-phospholipase protein[J].Inflammation Research.2004(4)
7Saglam A,Hayran M,Uner AH,et al.immunohistochemical expression of multidrug resistance proteins in mature T/NK-cell lymphomas[J].APMIS,2008,116(9):791-800.
8Han X,Zheng T,Foss FM,et al.Genetic polymorphisms in the metabolic pathway and non-Hodgkin lymphoma survival[J].Am J Hematol,2010,85(1):51-56.
9Thieblemont C,Rolland D,Baseggio L,et al.Comprehensive analysis of GST-pi expression in B-cell lymphomas j correlation with histological subtypes and survival[J].Leuk Lymphoma,2008,49(7):1403-1406.
10Hohaus S,Di Ruscio A,Di Febo A,et al.Glutathione S-transferase Pl genotype and prognosis in Hodgkin's lymphoma[J].Clin Cancer Res,2005,11(6):2175-2179.
